Publication | Open Access
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
122
Citations
21
References
2017
Year
| Year | Citations | |
|---|---|---|
Page 1
Page 1